TY - JOUR AU - Aharoni, R. PY - 2013 DA - 2013// TI - The mechanism of action of glatiramer acetate in multiple sclerosis and beyond JO - Autoimmun Rev VL - 12 UR - https://doi.org/10.1016/j.autrev.2012.09.005 DO - 10.1016/j.autrev.2012.09.005 ID - Aharoni2013 ER - TY - JOUR AU - Koch-Henriksen, N. AU - Sørensen, P. S. PY - 2010 DA - 2010// TI - The changing demographic pattern of multiple sclerosis epidemiology JO - Lancet Neurol VL - 9 UR - https://doi.org/10.1016/S1474-4422(10)70064-8 DO - 10.1016/S1474-4422(10)70064-8 ID - Koch-Henriksen2010 ER - TY - JOUR AU - Polman, C. H. AU - O'Connor, P. W. AU - Havrdova, E. AU - Hutchinson, M. AU - Kappos, L. AU - Miller, D. H. AU - Phillips, J. T. AU - Lublin, F. D. AU - Giovannoni, G. AU - Wajgt, A. AU - Toal, M. AU - Lynn, F. AU - Panzara, M. A. AU - Sandrock, A. W. PY - 2006 DA - 2006// TI - A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa044397 DO - 10.1056/NEJMoa044397 ID - Polman2006 ER - TY - JOUR AU - Comi, G. AU - Filippi, M. AU - Wolinsky, J. S. PY - 2001 DA - 2001// TI - European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group JO - Ann Neurol VL - 49 UR - https://doi.org/10.1002/ana.64 DO - 10.1002/ana.64 ID - Comi2001 ER - TY - JOUR AU - The, I. F. N. B. AU - Group, M. S. S. PY - 1993 DA - 1993// TI - Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial JO - Neurology VL - 43 UR - https://doi.org/10.1212/WNL.43.4.655 DO - 10.1212/WNL.43.4.655 ID - The1993 ER - TY - JOUR AU - Rudick, R. A. AU - Stuart, W. H. AU - Calabresi, P. A. AU - Confavreux, C. AU - Galetta, S. L. AU - Radue, E. W. AU - Lublin, F. D. AU - Weinstock-Guttman, B. AU - Wynn, D. R. AU - Lynn, F. AU - Panzara, M. A. AU - Sandrock, A. W. PY - 2006 DA - 2006// TI - Natalizumab plus interferon beta-1a for relapsing multiple sclerosis JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa044396 DO - 10.1056/NEJMoa044396 ID - Rudick2006 ER - TY - JOUR AU - Coyle, P. K. PY - 2008 DA - 2008// TI - Switching algorithms: from one immunomodulatory agent to another JO - J Neurol VL - 255 UR - https://doi.org/10.1007/s00415-008-1007-3 DO - 10.1007/s00415-008-1007-3 ID - Coyle2008 ER - TY - JOUR AU - Goodin, D. S. AU - Frohman, E. M. AU - Hurwitz, B. AU - O'Connor, P. W. AU - Oger, J. J. AU - Reder, A. T. AU - Stevens, J. C. PY - 2007 DA - 2007// TI - Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology JO - Neurology VL - 68 UR - https://doi.org/10.1212/01.wnl.0000258545.73854.cf DO - 10.1212/01.wnl.0000258545.73854.cf ID - Goodin2007 ER - TY - JOUR AU - Rio, J. AU - Tintore, M. AU - Sastre-Garriga, J. AU - Nos, C. AU - Castilló, J. AU - Tur, C. AU - Comabella, M. AU - Montalban, X. PY - 2012 DA - 2012// TI - Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response JO - Eur J Neurol VL - 19 UR - https://doi.org/10.1111/j.1468-1331.2011.03648.x DO - 10.1111/j.1468-1331.2011.03648.x ID - Rio2012 ER - TY - JOUR AU - Freedman, M. S. AU - Selchen, D. AU - Arnold, D. L. AU - Prat, A. AU - Banwell, B. AU - Yeung, M. AU - Morgenthau, D. AU - Lapierre, Y. PY - 2013 DA - 2013// TI - Treatment optimization in MS: Canadian MS Working Group updated recommendations JO - Can J Neurol Sci VL - 40 UR - https://doi.org/10.1017/S0317167100014244 DO - 10.1017/S0317167100014244 ID - Freedman2013 ER - TY - JOUR AU - Hartung, H. P. AU - Montalban, X. AU - Sorensen, P. S. AU - Vermersch, P. AU - Olsson, T. PY - 2011 DA - 2011// TI - Principles of a new treatment algorithm in multiple sclerosis JO - Expert Rev Neurother VL - 11 UR - https://doi.org/10.1586/ern.11.15 DO - 10.1586/ern.11.15 ID - Hartung2011 ER - TY - JOUR AU - Johnson, K. P. PY - 2012 DA - 2012// TI - Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis JO - Expert Rev Neurother VL - 12 UR - https://doi.org/10.1586/ern.12.25 DO - 10.1586/ern.12.25 ID - Johnson2012 ER - TY - JOUR AU - Scott, L. J. PY - 2013 DA - 2013// TI - Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis JO - CNS Drugs VL - 27 UR - https://doi.org/10.1007/s40263-013-0117-3 DO - 10.1007/s40263-013-0117-3 ID - Scott2013 ER - TY - JOUR AU - Ziemssen, T. AU - Bajenaru, O. A. AU - Carrá, A. AU - Klippel, N. AU - Sá, J. C. AU - Edland, A. AU - Frederiksen, J. L. AU - Heinzlef, O. AU - Karageorgiou, K. E. AU - Lander Delgado, R. H. AU - Landtblom, A. M. AU - Macías Islas, M. A. AU - Tubridy, N. AU - Gilgun-Sherki, Y. PY - 2014 DA - 2014// TI - A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial JO - J Neurol VL - 261 UR - https://doi.org/10.1007/s00415-014-7446-0 DO - 10.1007/s00415-014-7446-0 ID - Ziemssen2014 ER - TY - JOUR AU - Kulesher, R. AU - Forrestal, E. PY - 2014 DA - 2014// TI - International models of health systems financing JO - J Hosp Admin VL - 3 ID - Kulesher2014 ER - TY - JOUR AU - Carrá, A. AU - Macias-Islas, M. A. AU - Gabbai, A. A. AU - Correale, J. AU - Bolaña, C. AU - Sotelo, E. D. AU - Bonitto, J. G. AU - Vergara-Edwards, F. AU - Vizcarra-Escobar, D. PY - 2011 DA - 2011// TI - Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America JO - Ther Adv Neurol Disord VL - 4 UR - https://doi.org/10.1177/1756285611423560 DO - 10.1177/1756285611423560 ID - Carrá2011 ER - TY - JOUR AU - Finkelsztejn, A. AU - Fragoso, Y. D. AU - Ferreira, M. L. AU - Lana-Peixoto, M. A. AU - Alves-Leon, S. V. AU - Gomes, S. AU - Damasceno, B. P. AU - Mendes, M. F. AU - Salgado, P. R. AU - Correa, E. C. AU - Comini-Frota, E. R. AU - Diniz, D. S. AU - Gama, P. D. AU - Kaimen-Maciel, D. R. AU - Morales, R. R. AU - Arruda, W. O. AU - Grzesiuk, A. K. AU - Khouri, J. M. AU - Lopes, J. S. AU - Rocha, C. F. AU - Domingues, R. AU - Gonçalves, M. V. AU - Lorenti, M. A. AU - Parolin, M. K. AU - Siquineli, F. AU - Tosta, E. D. AU - Brooks, J. B. AU - Gallina, A. S. AU - Melges, L. D. AU - Ruocco, H. H. PY - 2011 DA - 2011// TI - The Brazilian database on pregnancy in multiple sclerosis JO - Clin Neurol Neurosurg VL - 113 UR - https://doi.org/10.1016/j.clineuro.2010.11.016 DO - 10.1016/j.clineuro.2010.11.016 ID - Finkelsztejn2011 ER - TY - JOUR AU - Miller, R. M. AU - Happe, L. E. AU - Meyer, K. L. AU - Spear, R. J. PY - 2012 DA - 2012// TI - Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians JO - J Manag Care Pharm VL - 18 ID - Miller2012 ER - TY - JOUR AU - Filippi, M. AU - Bozzali, M. AU - Rovaris, M. AU - Gonen, O. AU - Kesavadas, C. AU - Ghezzi, A. AU - Martinelli, V. AU - Grossman, R. I. AU - Scotti, G. AU - Comi, G. AU - Falini, A. PY - 2003 DA - 2003// TI - Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis JO - Brain VL - 126 UR - https://doi.org/10.1093/brain/awg038 DO - 10.1093/brain/awg038 ID - Filippi2003 ER - TY - JOUR AU - Stefano, N. AU - Narayanan, S. AU - Francis, G. S. AU - Arnaoutelis, R. AU - Tartaglia, M. C. AU - Antel, J. P. AU - Matthews, P. M. AU - Arnold, D. L. PY - 2001 DA - 2001// TI - Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability JO - Arch Neurol VL - 58 UR - https://doi.org/10.1001/archneur.58.1.65 DO - 10.1001/archneur.58.1.65 ID - Stefano2001 ER - TY - JOUR AU - Gajofatto, A. AU - Bacchetti, P. AU - Grimes, B. AU - High, A. AU - Waubant, E. PY - 2009 DA - 2009// TI - Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis JO - Mult Scler VL - 15 UR - https://doi.org/10.1177/1352458508096687 DO - 10.1177/1352458508096687 ID - Gajofatto2009 ER -